COMPANY

Neomorph

HQ: San Diego, CA source · neomorph.com ↗

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: Clear Cell Renal Cell Carcinoma Renal Cell Carcinoma RCC Clear Cell Renal Cell Carcinoma Metastatic ccRCC VHL-Associated Clear Cell Renal Cell Carcinoma VHL-Associated Renal Cell Carcinoma Kidney Cancer Metastatic Kidney Cancers NEO-811

$100.0MRaised (2 yrs)1Trials (company is sponsor)

Raises and deals from press releases

Raise Series B · $100M · announced Apr 13, 2026 Company release ↗
Source quote
- Apr 13, 2026 · Company release ↗
  “Neomorph Announces Closing of $100 Million Series B Financing”
Deal AbbVie deal · up to $1.64B total · announced Jan 23, 2025 Company release ↗
Source quote
- Jan 23, 2025 · Company release ↗
  “Under terms of the agreement, Neomorph will receive an upfront payment from AbbVie, and is eligible to receive up to $1.64 billion in aggregate option fees and milestones”
Deal Biogen deal · amount not disclosed · announced Oct 29, 2024 Company release ↗
Source quote
- Oct 29, 2024 · Company release ↗
  “(Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s”
Deal Novo Nordisk deal · up to $1.46B total · announced Feb 26, 2024 Company release ↗
Source quote
- Feb 26, 2024 · Company release ↗
  “Collaboration leverages Neomorph’s leading molecular glue discovery platform and Novo Nordisk’s extensive expertise in cardiometabolic and rare diseases Total potential deal value of $1.46B across multiple targets SAN DIEGO, Feb. 26, 2024 /PRNewswire/ — Neomorph, Inc”

Raises announced in these releases: $100M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Apr 13, 2026 Raise Private equity round — Series B: $100M (total, as published), announced Apr 13, 2026. Source: company release on GlobeNewswire. source ↗
Apr 13, 2026 Raise Series B · $100M source ↗
Dec 19, 2025 Trial start 1: Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma source ↗

Upcoming milestones

2027-01 (ESTIMATED) · 1 · Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma · NCT07300241

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $100.0M. Last 2 years.

Apr 13, 2026 Private equity round — Series B: $100M (total, as published), announced Apr 13, 2026. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07300241	Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma	1	Recruiting	Dec 19, 2025	2027-01 (estimated)